Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ICTAN: Adjuvant Icotinib in Stage IIA-IIIA EGFR-mutant NSCLC
NCT01996098Phase 3Terminated
- Sponsor
- Sun Yat-sen University
- Start
- Jan 2014
- Primary completion
- Dec 2021
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 3 trial of icotinib in non-small cell lung cancer (NSCLC), sponsored by Sun Yat-sen University. Started Jan 2014; status: terminated.
02
Drugs
icotinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT01996098.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01996098.